Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation

Berenguer M, Palau A, Aguilera V, Rayon JM, Juan FS, Prieto M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant. 2008;8(3):679-687.

Publication Type:

Journal Article

Authors:

Berenguer, M.; Palau, A.; Aguilera, V.; Rayon, J.M.; Juan, F.S.; Prieto, M.

Source:

Am J Transplant, Volume 8, Issue 3, p.679-687 (2008)

Keywords:

Adult, Aged, Antiviral Agents, diagnosis, Disease, drug therapy, Female, Genotype, genotype 1, HCV, hepatitis, Hepatitis C, hepatitis C virus, Hepatitis C,Chronic, Humans, interferon, Life, Liver, Liver Cirrhosis, Liver Transplantation, Male, Middle Aged, Mortality, nonresponder, Patients, pegylated, pegylated interferon, Recurrence, Research, Research Support, Retrospective Studies, Ribavirin, Risk, Spain, surgery, Survival, SVR, therapeutic use, therapy, transplantation, Treatment Outcome, virology

Cited On:

When and in Whom to Initiate HCV Therapy

External Third-party Web Link:

http://www.ncbi.nlm.nih.gov/pubmed/18294165

Export Citation:

RIS Format

Top